29 Mar 2018 Roy Franco No Comments
Blog, Medicare Advantage Part C, Pharma Part D, Trial Practice
A new decision was handed down from the U.S. Court of Appeals for the 11th Circuit in the Barbara J. Harvey v. Florida Health Sciences Center, Inc. this month. Here, the Plaintiff pursued a medical malpractice claim against a hospital for her husband’s death. The hospital agreed to binding arbitration on the sole issue of damages to avoid a lawsuit. …
READ MORE
28 Mar 2018 Roy Franco No Comments
Blog, Medicare Advantage Part C, Pharma Part D
The Medicare Advocacy Recovery Coalition (MARC) is an organization made up of insurance companies, third party administrators, defense firms, plaintiff firms and MSP compliance companies. MARC recently announced an important new legislative initiative. Primary Plans which are plagued unfairly by MSP private cause of action claims would have an important tool at their disposal, once the legislation is introduced and …
READ MORE
14 Sep 2017 Jesse Hamby No Comments
About Franco Signor, Legal/Legislative News, Pharma Part D
Click here to read the entire article.
20 Feb 2017 Heather Sanderson No Comments
Blog, Legal/Legislative News, Pharma Part D
On Thursday, February 16, Congressman Tim Murphy (R-PA) and Congressman Ron Kind (D-WI) re-introduced the Secondary Payer Advancement, Rationalization, and Clarification Act (SPARC Act – H.R. 1122) into the US. House of Representatives. For our prior blog and a detailed overview of the SPARC Act, click here. For Congressman Tim Murphy’s press release on the SPARC Act’s re-introduction, click here. …
READ MORE
18 Oct 2016 Roy Franco No Comments
Blog, Legal/Legislative News, Medicare Jurisdiction, Medicare Secondary Payer News, Pharma Part D, Reimbursements
The Medicare Advocacy Recovery Coalition (MARC) worked diligently over the past eighteen months to develop and introduce the Secondary Payer Advancement, Rationalization and Clarification Act of 2016 (SPARC). Representatives Tim Murphy (18th District Pennsylvania, Republican) and Ron Kind (3rd District Wisconsin, Democrat) sponsored this bipartisan legislation that was immediately referred to the two committees of jurisdiction over Medicare – House …
READ MORE
26 Sep 2016 Roy Franco No Comments
Blog, Franco Signor News, Legal/Legislative News, Pharma Part D
On September 24, 2016, legislation was introduced to clarify Part D Drug Plans reimbursement rights under the Medicare Secondary Payer law. The legislation will reinforce for these Plans a clear right of subrogation and improvement in Section 111 MMSEA data for improved coordination. To learn more about the proposed legislation, click here. Congratulations to the Medicare Advocacy Recovery Coalition for …
READ MORE
29 Sep 2014 Roy Franco No Comments
Blog, Medicare Conditional Payments, Medicare Jurisdiction, Medicare Secondary Payer News, Pharma Part D, Reimbursements, Trial Practice
This past March we wrote about the Magistrate’s recommendation to the Judge handling the Humana Insurance Co. v. Farmers Texas County Mutual Insurance Co. Cause No. 13-CV-611-LY to dismiss the claim. Our analysis of that recommendation can be found here. In brief, we compared the decision process to a boxing match that would inevitably end up in the appellate courts. …
READ MORE
21 Aug 2014 sshamrock No Comments
The Centers for Medicare & Medicaid Services (CMS) issued an important alert on August 19, 2014. An issue of contention with the Agency by the Industry has been the pricing of prescription drugs. Typically allocations returned with a counter higher letter by the review contractor are due to a conflict for the proposed cost of pharmaceuticals. These discrepancies has led …
READ MORE
23 Jan 2014 Roy Franco No Comments
Blog, Medicare Advantage Part C, Pharma Part D
We previously blogged about lawsuits brought by Humana against Farmers Insurance in four jurisdictions across the country. We have been informed that Humana voluntarily dismissed three of the complaints (Tennessee, Missouri and Kansas), however the case brought in Texas is moving forward. Recently, Farmers moved to dismiss Human’s Texas litigation. That motion is being rigorously opposed by Humana in the …
READ MORE
19 Apr 2013 Roy Franco No Comments
On April 16, 2013, the Food & Drug Administration announced that it will not be approving generic OxyContin, the same day the patent expired for the abuse resistant type. The FDA action appears in line with national concern over the meteoric rise in opiates use since 2000. Today, this drug turns into a gummy substance if an addict attempts to …
READ MORE
